Eupraxia Pharmaceuticals Inc. (TSX: EPRX)
Canada
· Delayed Price · Currency is CAD 4.700
-0.330 (-6.56%)
Nov 21, 2024, 1:47 PM EST
Eupraxia Pharmaceuticals Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2017 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2017 |
| Net Income | -28.22 | -28.22 | -18.49 | -23.96 | -4 | -7.18 | Upgrade
|
| Depreciation & Amortization | 0.16 | 0.16 | 0.15 | 0.11 | 0.12 | 0.2 | Upgrade
|
| Loss (Gain) From Sale of Assets | -0.01 | 0 | 0.01 | - | 0.13 | - | Upgrade
|
| Stock-Based Compensation | 2.51 | 1.41 | 1.43 | 3.43 | 0.23 | 0.54 | Upgrade
|
| Other Operating Activities | -2.54 | 0.61 | 0.99 | 5.97 | 1.53 | 0.78 | Upgrade
|
| Change in Accounts Receivable | -0.04 | -0.1 | 0.23 | 0.19 | 0.73 | 0.14 | Upgrade
|
| Change in Accounts Payable | -0.94 | 0.58 | 1.32 | -0.63 | 0.85 | 0.31 | Upgrade
|
| Change in Other Net Operating Assets | -0.83 | 4.88 | -0.04 | 0.07 | 0 | 0.03 | Upgrade
|
| Operating Cash Flow | -29.92 | -20.68 | -14.4 | -14.83 | -0.4 | -5.17 | Upgrade
|
| Capital Expenditures | -0.11 | -0.07 | -0.24 | -0.43 | - | -0.01 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.03 | - | 0 | - | 0.08 | - | Upgrade
|
| Investment in Securities | - | - | 10.07 | -9 | - | - | Upgrade
|
| Other Investing Activities | - | - | - | -5.02 | -0.06 | -1.89 | Upgrade
|
| Investing Cash Flow | -0.08 | -0.07 | 9.83 | -14.45 | 0.02 | -1.9 | Upgrade
|
| Short-Term Debt Issued | - | - | - | 0.1 | 0.71 | 3.02 | Upgrade
|
| Long-Term Debt Issued | - | - | - | 12.75 | - | 4.5 | Upgrade
|
| Total Debt Issued | - | - | - | 12.85 | 0.71 | 7.52 | Upgrade
|
| Long-Term Debt Repaid | - | -0.14 | -0.14 | -0.59 | -1.1 | -0.12 | Upgrade
|
| Net Debt Issued (Repaid) | -9.22 | -0.14 | -0.14 | 12.27 | -0.39 | 7.4 | Upgrade
|
| Issuance of Common Stock | 23.22 | 21.16 | 10.94 | 37.83 | - | - | Upgrade
|
| Other Financing Activities | - | - | - | - | -0.24 | - | Upgrade
|
| Financing Cash Flow | 13.99 | 21.01 | 10.8 | 50.1 | -0.63 | 7.4 | Upgrade
|
| Foreign Exchange Rate Adjustments | 0.11 | 0.82 | -0.51 | -0.08 | -0 | - | Upgrade
|
| Net Cash Flow | -15.9 | 1.08 | 5.73 | 20.74 | -1.01 | 0.33 | Upgrade
|
| Free Cash Flow | -30.03 | -20.76 | -14.63 | -15.26 | -0.4 | -5.18 | Upgrade
|
| Free Cash Flow Per Share | -0.94 | -0.86 | -0.76 | -1.23 | -0.07 | -0.85 | Upgrade
|
| Cash Interest Paid | 0.55 | 0.6 | 0.33 | 0.58 | 0.12 | 0.44 | Upgrade
|
| Levered Free Cash Flow | -19.05 | -10.78 | -8.72 | -16.43 | -0.75 | -5.43 | Upgrade
|
| Unlevered Free Cash Flow | -18.52 | -10.05 | -8.11 | -15.66 | 0.43 | -4.52 | Upgrade
|
| Change in Net Working Capital | 1.38 | -5.86 | -1.56 | 7.57 | -1.49 | 1.4 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.